TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

TCRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

TScan Therapeutics, Inc.NASDAQ: TCRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 129.91M shares rose 0.2% year over year, behind the +7.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +75.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.2% toward the trailing-twelve-month pace of +7.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
129.91M+0.0% QoQ
Last fiscal yearDec 2025
129.86M+16.0% YoY
LTMMar 2026
129.84M+7.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.2%——
1 year+16.0%——
3-year CAGR+75.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
129.86M USD
Year-over-year change
+16.0%
4-year CAGR
+52.7%

Weighted Avg Shares (Diluted) vs competitors

How TCRX compares with its peers on the latest reported figures

  • TCRX's LTM Mar 2026 weighted avg shares (diluted) of 129.84M shares is the 2nd highest of the 10 companies compared; the peer median is 38.56M shares.
  • Its year-over-year change of +7.6% is the 7th highest of 10, against a peer median of +14.7%.
  • Over three fiscal years its annual growth of +75.4% compares with a peer median of +11.2%.
TCRX Competitors Peer median
Weighted Avg Shares (Diluted) for TCRX and competitors
Company Period LTM YoY 3-year CAGR
VXRTVaxart, Inc.LTM Mar 2026232.46M +14.7%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
FBIOFortress Biotech, Inc.LTM Mar 202695.09M +349.0%+261.1%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
XBITXBiotech Inc.LTM Mar 202630.49M +0.1%+0.1%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
NTRBNutriband Inc.LTM Apr 202611.9M +8.4%+11.2%
ACETAdicet Bio, Inc.LTM Mar 20267.26M +28.8%+39.0%
Peer median (excluding TCRX) 38.56M+14.7%+11.2%

Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.14M13.54M21.05M2.82M10.33M
Cost of Revenue00002.87M
Gross Profit10.14M13.54M21.05M2.82M7.46M
Gross Margin100.0%100.0%100.0%100.0%72.2%
Research & Development44.95M59.82M88.15M107.35M114.15M
Selling, General & Admin13.83M20.35M25.49M29.56M31.99M
Operating Expenses58.78M80.17M114.51M137.64M143.27M
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
EBITDA(45.3M)(59.91M)(80.1M)(119.74M)(124.13M)
EBITDA Margin-446.7%-442.6%-380.5%-4252.1%-1202.2%
Operating Income(48.64M)(66.64M)(93.46M)(134.82M)(135.81M)
Operating Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%
Interest Income16K1.59M8M12.07M8.82M
Interest Expense01.18M3.76M3.65M2.77M
Other Income / Expenses16K415K4.24M7.32M6.05M
Income Before Tax(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Pre-Tax Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
Income Tax Expense00000
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Net Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
EPS (Basic)(2.03)(2.74)(1.36)(1.14)(1.00)
EPS (Diluted)(2.03)(2.74)(1.36)(1.14)(1.00)
Weighted Avg Shares23.91M24.05M65.6M111.99M129.86M
Weighted Avg Shares (Diluted)23.91M24.05M65.6M111.99M129.86M

TScan Therapeutics, Inc.

NASDAQ:TCRX

Intrinsic Alpha fair value

Locked

Current Price

$0.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.